Behavioural Pharmacology
September 1, 2019
Agnieszka Pałucha-Poniewiera, K. Podkowa, Andrzej Pilc
Ketamine has been shown to induce a rapid antidepressant effect on patients with depression. In many animal models, both rapid and sustained antidepressant activities were also found in response to an antagonist of group II metabotropic glutamate receptors, LY341495, and its mechanism of action seemed to be similar in many ways to the action of ketamine. It has also been found that LY341495...
The International Journal of Neuropsychopharmacology
August 28, 2019
Jiancheng Zhang, Youge Qu, Lijia Chang et al.
56 citations
BACKGROUND: A recent study demonstrated that spine formation rates by ketamine in the prefrontal cortex (PFC) were not altered at 3-6 h following a single injection, but were markedly altered at 12-24 h. Here, we investigated the acute (3 h post-treatment) effects of (R)-ketamine in the decreased spine density in the medial PFC (mPFC) and hippocampus in susceptible mice after chronic social...
Carolina Digital Repository
August 16, 2019
Mary S. Garner
Background: Introduction: The average person has up to 15% lifetime risk for developing depression. Major depressive disorder symptoms can include a depressed mood, such as feeling sad or having more anger than normal, changes in appetite, loss of interest in activities or hobbies, psychomotor agitation or retardation, loss of energy, feelings of worthlessness or guilt, decreased ability to...
Behavioural Brain Research
August 13, 2019
Andrew J. Polis, Paul J. Fitzgerald, Pho J. Hale et al.
58 citations
Discovering that the anesthetic drug ketamine has rapidly acting antidepressant effects in many individuals with major depression is one of the most important findings in clinical psychopharmacology in recent decades. The initial report of these effects in human subjects was based on a foundation of rodent preclinical studies carried out in the 1990s, and subsequent investigation has included...
BMJ Open
August 1, 2019
Karen Lascelles, Lisa Marzano, Fiona Brand et al.
Objective It is recognised that ketamine treatment can reduce suicidal ideation (SI) in people with depression, at least in the short term. However, information is lacking on patients’ perspectives on such effects. Studying these can contribute to greater understanding of the mechanisms underlying impact of ketamine treatment on SI. The aim of this study was to investigate patients’ reports of...
International Immunopharmacology
August 1, 2019
Daiyue Chang, Jinghua Zhao, Xintong Zhang et al.
Depression has become a common mental illness, and studies have shown that neuroinflammation is associated with depression. Ketamine is a rapid antidepressant. In order to obtain better antidepressant effects, it is necessary to explore the efficacy of combination therapy with ketamine and other antidepressants. DHA is an unsaturated fatty acid with excellent application prospects due to its...
Behavioural Brain Research
August 1, 2019
Zhongwei Xiong, Yuko Fujita, Kai Zhang et al.
Inflammatory bone markers may play a role in the antidepressant actions of (R)-ketamine in susceptible mice after chronic social defeat stress (CSDS). In this study, we compared the effects of (R)-ketamine and its final metabolite (2R,6R)-hydroxynorketamine (HNK) in depression-like phenotypes, inflammatory bone markers and bone mineral density (BMD) in CSDS susceptible mice. We measured plasma...
Heliyon
August 1, 2019
Steve Best, Dan G. Pavel, Natalie Haustrup
34 citations
Background Both transcranial magnetic stimulation (TMS) and infused ketamine are recognized treatments for patients suffering from major depressive disorder (MDD). A novel therapy named combination TMS with ketamine (CTK) is introduced. This retrospective review examined the safety and clinical benefits of CTK in patients suffering from treatment-resistant depression (TRD) during the routine...
Drug Design, Development and Therapy
August 1, 2019
Alexandrine Corriger, G. Pickering
197 citations
Abstract Depression is the third leading cause of disability in the world. Depressive symptoms may be reduced within several weeks after the start of conventional antidepressants, but treatment resistance concerns one-third of patients who fail to achieve recovery. Over the last 20 years, ketamine, an antagonist of the N-methyl-D-aspartate receptor, has been described to have antidepressant...
The British Journal of Psychiatry
August 1, 2019
Álvaro López-díaz, Manuel Murillo-Izquierdo, Elisa Moreno-Mellado
21 citations
Ketamine therapy for treatment-resistant depression in European national health systems may only be considered after attempting all evidence-based antidepressant strategies outlined in clinical guidelines. This paper seeks to explain the ethical, regulatory and procedural framework for the off-label use of ketamine for treatment-resistant depression within a public healthcare system.Declaration...